VNDA
VNDA
NASDAQ · Biotechnology

Vanda Pharmaceuticals Inc

$3.82
+0.23 (+6.41%)
As of Nov 7, 10:20 PM ET ·
Financial Highlights (FY 2026)
Revenue
212.56M
Net Income
-216,864,356
Gross Margin
94.0%
Profit Margin
-102.0%
Rev Growth
-5.3%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 94.0% 94.0% 30.7% 30.7%
Operating Margin -69.9% -63.0% 14.8% 14.7%
Profit Margin -102.0% -96.9% 10.4% 10.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 212.56M 224.44M 122.09M 118.94M
Gross Profit 199.72M 210.88M 37.47M 36.50M
Operating Income -148,688,066 -141,293,695 18.10M 17.45M
Net Income -216,864,356 -206,079,527 12.67M 12.10M
Gross Margin 94.0% 94.0% 30.7% 30.7%
Operating Margin -69.9% -63.0% 14.8% 14.7%
Profit Margin -102.0% -96.9% 10.4% 10.2%
Rev Growth -5.3% -5.3% +22.8% +0.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.47M 2.47M 139.11M 164.30M
Total Equity 107.67M 107.67M 288.85M 284.24M
D/E Ratio 0.02 0.02 0.48 0.58
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -141,799,715 -142,233,902 21.61M 18.83M
Free Cash Flow — — 20.08M 12.24M